Brief report · 30 Nov 2024
Conference abstractPublished 10 Aug 2015
B cell targeted strategies
Cairo University Hospitals, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With the evolution of biologic drugs in the last one and half decades, the treatment paradigm of autoimmune diseases experienced a dramatic shift that ultimately improved outcome in the setting of refractory illness. Targeting the antibody producing B lymphocyte at its different developmental stages represents one important approach nowadays in the treatment strategy of a multiplicity of autoimmune diseases especially rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The production and differentiation of the B cells passes through various developmental stages with the earliest identifiable precursor being the stem cells also known as the progenitor B-Cell, then pro-B, pre-B, immature B, virgin B-Cell and plasma cells. Therapeutic antibodies to cell surface receptors on B lymphocytes as well as their survival factors have been extensively tested with the anti-CD-20 therapy Rituximab being on top of the list used for refractory rheumatoid and in refractory systemic lupus particularly after failure of conventional immunosuppressive drugs, in addition to anti B lymphocyte survival factor anti- BLys like Atacicept and Belimumab, the recently approved biologic therapy for systemic lupus erythematosus. Other uprising B cell targeted strategies include Blisimod (A623) soluble and membrane bound BLyS, and Tabalumab (LY2127399) soluble and membrane BLyS, such novel drugs are being currently evaluated in SLE and RA.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 29 Jun 2026
Immunomodulatory Therapeutics: Advancing Immune System Control Through Targeted Medical Strategies
Rapid communication · 27 Feb 2025
Targeting NLRP3 Inflammasome Pathway in Cancer: A Novel Therapeutic Strategy
Opinion · 27 Feb 2025
Targeting Inflammatory Pathways for Cancer Prevention: Current Strategies and Future Directions
Editorial · 30 Jul 2024
Targeting Cytokine Storms in COVID-19: Current Strategies and Future Directions
More from this journal
The newest in Immunome Research.
Short communication · 29 Dec 2025
Beyond the Surface: Cellular Immune Responses in Uncharted Territories
Commentary · 27 Dec 2025
Stress-Induced Remodeling of Immune Cell Phenotypes
Perspective · 26 Dec 2025
Immune System Dysregulation in Complex Multisystem Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunome Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Reem Hamdy A Mohammed”

